Genenta Science S.p.A.’s Initial Public Offering On Nasdaq

Goodwin Procter advised the underwriters on the deal.

Genenta Science S.p.A.’s (Nasdaq: GNTA) announced its upsized initial public offering, making history as the first Italian biotech to be listed on the Nasdaq.

The offering consisted of 2.4 million American Depositary Shares at a public offering price of $11.50 per ADS. Genenta also sold 720,114 ordinary shares reserved for subscription by its existing shareholders at a price of $11.50 per share. The gross proceeds from the offering, including ordinary shares, were approximately $36 million before deducting underwriting and advisory fees and offering expenses. Genenta has granted the underwriters an option for a period of 30 days from the date of the final prospectus to purchase an additional 360,000 ADSs, which, if exercised in full, will increase gross proceeds from the offering to approximately $40 million.

Genenta is a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon™.

Roth Capital Partners and Maxim Group acted as underwriters of the offering.

The Goodwin team was led by Thomas Levato and Ettore Santucci and included, among others, Kristen Kennedy, Mingshu Liu, and Adanna Uwazurike for capital market matters, Alexander Varond and Elizabeth Mulkey for regulatory matters, and Suhrid Wadekar for intellectual property matters.

The LCA Studio Legale team was led by Andrea Messuti, assisted by Stefano Giannone Codiglione, Flavia Visco and Edoardo Berni. The team also included Agostino Migone de Amicis, Alberto Mocchi, Ranieri Romani, Zuleika Palma, Gianluca De Cristofaro and Matteo Di Lernia.

The Giovannelli e Associati team was led by Andrea Bartolucci and Gianvittorio Giroletti Angeli. Additional asisstance was provided by Marco Tapparo, Annalisa Zorzut, Camilla Lanzafame, Giuseppe Matarazzo and Riccardo Pontremoli.

The Loeb & Loeb team was led by Mitchell Nussbaum and Norwood Beveridge. it also included David Levine, Dinh Doan, James Czaban and Kathleen Gersh.

The Studio Spada & Partners team was led by Paolo Mandelli and Bernardo Porcellini.

The Emmet Marvin & Martin team was led by Cristina Cobb.




Involved fees earner: Cristina Cobb – Emmet, Marvin & Martin, LLP; Andrea Bartolucci – Giovannelli e Associati Studio Legale; Gianvittorio Giroletti Angeli – Giovannelli e Associati Studio Legale; Camilla Lanzafame – Giovannelli e Associati Studio Legale; Giuseppe Matarazzo – Giovannelli e Associati Studio Legale; Riccardo Pontremoli – Giovannelli e Associati Studio Legale; Marco Tapparo – Giovannelli e Associati Studio Legale; Annalisa Zorzut – Giovannelli e Associati Studio Legale; Kristen Kennedy – Goodwin Procter; Thomas Levato – Goodwin Procter; Mingshu Liu – Goodwin Procter; Ettore Santucci – Goodwin Procter; Alexander Varond – Goodwin Procter; Suhrid Wadekar – Goodwin Procter; Norwood Beveridge Jr. – Loeb & Loeb LLP; James Czaban – Loeb & Loeb LLP; Dinh Doan – Loeb & Loeb LLP; Kathleen Gersh – Loeb & Loeb LLP; David Levine – Loeb & Loeb LLP; Mitchell Nussbaum – Loeb & Loeb LLP; Paolo Lorenzo Mandelli – Spada Partners; Bernardo Porcellini – Spada Partners;

Law Firms: Emmet, Marvin & Martin, LLP; Giovannelli e Associati Studio Legale; Goodwin Procter; Loeb & Loeb LLP; Spada Partners;

Clients: Bank of New York Mellon; Genenta Science; Maxim Group LLC; Roth Capital Partners, LLC;


Author: Michael Patrini